According to Prof. Dr. Maj. Gen. Hoang Van Luong, Deputy Director of the Defense Ministry’s Military Medical University, the volunteers are in stable health. None has reported unexpected side effects, he said.
Results from the first two trial phases showed that all volunteers developed antibodies against the SARS-CoV-2 virus.
NanoCovax was developed by the Nanogen Pharmaceutical Biotechnology JSC based on recombinant DNA/protein technology. It went through a first-phase trial beginning in December, 2020, and a second phase beginning in February, 2021. The third phase began on June 11, 2021.